The aim of the present study was to determine whether EMMPRIN (extracellular matrix metalloproteinase inducer) is present and is up-regulated in human aneurysmal aortas, and to assess a possible association with AngII (angiotensin II)-induced aneurysm formation. The presence of EMMPRIN was assessed in 41 surgical specimens from patients with a TAA (thoracic aortic aneurysm) (Type A aortic dissection, n = 12; Type B aortic dissection, n = 7; and TAA without dissection, n = 7) or an AAA (abdominal aortic aneurysm, n = 15) by immunohistochemistry. EMMPRIN expression in aortic aneurysm tissues was compared with 12 aortas obtained during autopsy (free of any vascular diseases), and scored for both staining intensity and the percentage of vascular cells stained. EMMPRIN protein levels in cultured human aortic SMCs (smooth muscle cells) following stimulation of AngII were analysed by Western blotting. Significant EMMPRIN immunoreactivity was detected in aortic aneurysm lesions from patients with TAAs and AAAs. In the aneurysmal wall, α-actin-positive SMCs were the main source of EMMPRIN. The frequency of EMMPRIN overexpression was significantly higher (P = 0.026) in TAAs with dissection (68.4 %) than TAAs without dissection (14.3 %). AngII stimulation up-regulated the expression of EMMPIRN in cultured human aortic SMCs, which was suppressed by the addition of the AT 1 R (AngII type 1 receptor) antagonist losartan. In conclusion, the present study is the first to report the expression of EMMPRIN in aortic aneurysmal diseases, and we speculate that EMMPRIN may be important in the pathogenesis of these diseases. Whether these abnormalities are potential therapeutic targets deserve further investigation.
INTRODUCTION
Aortic aneurysms are the major disease processes affecting the aorta and are becoming a relatively common cause of death due to rupture or dissection. The most common location for aneurysms is the infrarenal abdominal aorta, followed by the ascending thoracic aorta. Although AAAs (abdominal aortic aneurysms) and TAAs (thoracic aortic aneurysms) without or with dissection have some important differences in pathology, these three types of aneurysmal disease share some similar pathological phenotypes, including remodelling of the aortic wall involving fragmentation and decreased elastic fibres in the tunica media [1] . From experimental and clinical studies, it is known that matrix conservation and degradation by MMPs (matrix metalloproteinases) play a major role in aortic aneurysmal disease formation and progression [2] [3] [4] [5] [6] [7] . EMMPRIN (extracellular MMP inducer; also known as basigin and CD147) is a cell-surface glycoprotein that belongs to the immunoglobulin superfamily. EMMPRIN has been reported to induce and activate the expression of MMPs in the myocardium and atherosclerotic plaque, and plays an important role in ventricular remodelling and atherogenic cell differentiation [8, 9] . Similarly, EMMPRIN may be expressed in human aortic aneurysms and play a role in ECM (extracellular matrix) remodelling and the pathogenesis of aortic aneurysmal diseases. However, the potential role of EMMPRIN in aneurysmal pathologies has not yet been characterized. There is increasing evidence from in vitro studies that local production of AngII (angiotensin II) may contribute to the development of aortic aneurysm pathologies [3, 10, 11] . Results obtained from pharmaceutical intervention in humans and animals strongly support this hypothesis [12] [13] [14] ; however, evidence for a role of AngII in the formation of human aortic aneurysm is not direct and is also under-researched. AngII-induced AAAs have highly heterogeneous cellular and ECM characteristics throughout the aorta, accompanied by increased expression and activity of MMPs [3, 14] . As EMMPRIN can alter the expression and activity of MMPs in various cell systems [8, 9, [15] [16] [17] , the present study was designed to determine whether EMMPRIN is present and up-regulated in the wall of human TAA and AAA, and to assess the possible association with AngII-induced aneurysm formation.
MATERIALS AND METHODS

Tissue collection
Aortic specimens (n = 41) were obtained from the central portion of the aneurysmal aorta of patients who were undergoing aortic reconstruction. The series included 26 cases of TAA (Type A aortic dissection, n = 12; Type B aortic dissection, n = 7; and TAA without dissection, n = 7) and 15 cases of AAA. Dissection was classified according to the Stanford classification, which defines any involvement of the ascending aorta as a Type A aortic dissection and exclusive dissection of the descending aorta as Type B aortic dissection. Aortic tissue from patients with hereditary connective tissue defects, such as Marfan's syndrome, traumatic aneurysms or luetic aortic aneurysms were excluded. Aortic dissection involving the abdominal aorta or isolated abdominal aortic dissection were not included in our present study. We also excluded samples from patients with a bicuspid aortic valve. The mean value of the maximum aortic aneurysm diameter was 6.8 + − 1.8 cm (range, 4-10 cm). Control specimens were obtained from 12 deceased subjects undergoing autopsy within 24 h of death due to non-cardiovascular disease. The entire aorta was retrieved and strips of aortic wall without atheromatous plaque were carefully excised from thoracic and abdominal aorta. The aneurysmal and normal aorta tissues were fixed in 10 % (v/v) formalin immediately after resection.
Clinical characteristics of subjects are shown in Table 1 . The mean age of patients with TAAs with dissection was significantly lower (P = 0.002) than patients with AAAs. The subjects with TAAs, AAAs and controls did not differ with regard to gender, smoking status, hypertension or diabetes.
The present study was conducted in accordance with the World Medical Association Declaration of Helsinki and was approved by the Local Research Ethics Committee. Informed consent was obtained from the subjects or from the patient's relatives in the case of control subjects.
Histology and immunohistochemistry
Tissue was fixed in formalin, processed and embedded in paraffin. Serial cross-sections (5 μm) of tissue were cut and attached on to poly-l-lysine-coated slides. Aortic sections were stained with haematoxylin and eosin, Masson's Trichrome for collagen and Verhoeff-Van Gieson for elastin. Immunohistochemistry was performed with EnVision TM Detection System, Peroxidase/ DAB, Rabbit/Mouse (K5007; DAKO), using mouse monoclonal antibodies to human EMMPRIN (Abcam), human monocytes/macrophages (CD68; DAKO) and α-SMA (smooth muscle α-actin; DAKO).
The paraffin sections were deparaffinized and rehydrated, boiled with citric acid for 5 min in order to reduce the non-specific binding of the antibodies and to increase the exposure of antigens, and finally cooled at room temperature (25
• C) for 20 min. Subsequently, the sections were treated with 0.3 % H 2 O 2 for 5 min to suppress endogenous peroxidase activity. Sections were then incubated with 10 % (v/v) normal goat serum (which served as a blocking agent for non-specific binding) in PBS for 20 min at room temperature. After blotting excess serum, the sections were incubated overnight at 4
• C with primary antibodies against EMMPRIN (1:40 dilution), α-SMA (1:100 dilution) and CD68 (1:500 dilution) in a moist chamber, and processed further using the EnVision TM Detection System Peroxidase/DAB, Rabbit/Mouse with biotinylated secondary antibodies [goat anti-(rabbit IgG) and goat anti-(mouse IgG); DAKO]. Immunohistochemical reactions were developed with DAB (diaminobenzidine) as the chromogenic peroxidase substrate, and the sections were counterstained with haematoxylin. The immunohistochemical specificity of the antibodies was confirmed using two types of negative controls: (i) substituting mouse non-immune IgG for the primary antibodies, and (ii) omitting the primary antibodies from the staining protocol.
Staining results were evaluated by two board-certified pathologists who were blinded to the clinical data. For each tissue sample, the fraction of immunostained cells was recorded, and the staining intensity was estimated on a four-step scale (negative is no staining, 1+ is weak staining, 2+ is moderate staining, and 3+ is strong staining). Aortas were then initially categorized into four groups according to arbitrarily predefined EMMPRIN scores (scores 0, 1, 2 and 3). The exact criteria for these groups were as follows [13] : 0, no staining at all; 1, 1+ staining regardless of positive cell percentages or 2+ staining of 30 % of cells; 2, 2+ staining of > 30 % of cells or 3+ staining of 50 % of cells; and 3, 3+ staining of > 50 % of cells. Discordant evaluations were adjusted using multihead microscopes and discussion with other observers.
Cell culture
Human aortic SMCs (smooth muscle cells) from healthy aortas were obtained from Cascade Biologics and were used up to passage 6. Human aortic SMCs were cultured according to the manufacturer's instructions, and were grown in Medium 231 with smooth muscle growth supplements (Cascade Biologics). For experiments, confluent cells were growth-arrested in Medium 231 without smooth muscle growth supplements. Cells were then incubated with AngII (10 −9 -10 −6 mol/l; Sigma) for 24 h in the absence or presence of the AT 1 R (AngII type 1 receptor) antagonist losartan (Merk).
Western blot analysis
Cell-associated EMMPRIN expression induced by cell treatments was assessed by Western blotting. After the indicated time interval, cells were collected and lysed in cell lysis buffer containing 50 mmol/l Tris/HCl (pH 7.4), 150 mmol/l NaCl, 1 mmol/l EDTA, 0.1 % SDS and 1 % (v/v) Nonidet P40. Immediately prior to cell lysis, 1 mmol/l PMSF and 10 mmol/l sodium fluoride were added to the lysis buffer. The cells were vortex-mixed for 30 min at 4
• C, then centrifuged at 12 000 g for 20 min at 4
• C. The protein concentration of cell lysate was determined using the Bio-Rad Laboratories DC protein assay. Equal amounts of proteins (20 μg/lane) were loaded on to a gel and were separated by SDS/PAGE under reducing conditions. Resolved proteins were electrophoretically transferred on to a PVDF Immobilon-P membrane (Bio-Rad Laboratories) using a Bio-Rad Laboratories wet transfer system. Protein transfer efficiency and size determination were verified using prestained protein markers (Fermentas). Membranes were blocked in TBST [Tris-buffered saline plus Tween 20; 10 mmol/l Tris/HCl (pH 8.0), 150 mmol/l NaCl and 0.05 % Tween 20] with 5 % (w/v) non-fat milk for 1 h at room temperature, followed by overnight incubation at 4
• C with the monoclonal anti-(human EMMPRIN) antibody (dilution 1:100; Abcam). After washing with TBST, the membranes were incubated for 1 h with an HRP (horseradish peroxidase)-conjugated goat anti-(mouse IgG) secondary antibody (Santa Cruz Biotechnology) diluted 1:5000 in TBST. The labelled proteins were detected by using enhanced chemiluminescence reagents (Pierce) and exposed to film (Kodak). After detection of EMMPRIN, the membranes were stripped with Western blotting stripping buffer (Pierce) and reprobed with a mouse anti-(human β-actin) antibody (dilution 1:3000; Santa Cruz Biotechnology) as a loading control, followed by a goat anti-(mouse IgG) antibody at a 1:5000 dilution (Santa Cruz Biotechnology). The intensities of the bands were quantified using Image J. 1.33u (National Institutes of Health).
Statistical analysis
A SPSS 11.5 software package was used for statistical analysis. Results are presented as means + − S.D. The normality of the distribution of data was evaluated using a Shapiro-Wilks one-sample test, and an F test was used to assess the homogeneity of variance. Comparisons were performed using an unpaired two-tailed Student's t test for normally distributed continuous variables, a Mann-Whitney U test for non-normally distributed variables, and a χ 2 test for categorical variables. When appropriate, a one-way ANOVA with post-hoc Bonferroni corrections was used to test for significant differences between the groups. A P value < 0.05 was considered to be statistically significant.
RESULTS
Histology and localization of immunoreactive EMMPRIN
Aneurysmal aortas revealed a loss of normal arterial morphology, which was unaltered in the control aortas. Verhoeff-Van Gieson and Masson's Trichrome staining of aortic sections from patients with TAA (without or with dissection) and AAA showed disruption and fragmentation of internal elastic lamellae, whereas elastin lamellae were clearly visible in control aortas (Figure 1 ).
Figure 2 Immunohistochemical staining of EMMPRIN in aortas from patients with TAAs with dissection (A-D), TAAs without dissection (E-H) and AAAs (I-L), and control aortas (M-P)
Representative immunohistochemical sections are shown. Serial consecutive sections from the same sample were used for the staining of EMMPRIN, α-SMA (SMCs) and CD68 (macrophages). Expression of EMMPRIN was significantly increased in the aortic walls from patients with TAA or AAA when compared with control specimens. Consecutive sections from the same sample were stained for EMMPRIN, α-SMA and CD68 (Figure 2) . A limitation of this approach is that these markers were not measured simultaneously in the same tissue section; however, staining in serial sections suggests, α-SMA-positive SMCs were the main source of EMMPRIN in the aneurysmal wall (results not shown). No EMMPRIN signals were detected in monocyte/macrophage-rich areas (CD68-positive cells). Immunoreactive EMMPRIN was not detected in the control aortas.
Higher frequency of EMMPRIN overexpression in TAA with dissection
The results of the EMMPRIN immunohistochemical staining were as follows: 19 patients (46.3 %) had a score of 3, ten patients (24.4 %) had a score of 2, seven patients (17.1 %) had a score of 1 and five patients (12.2 %) had a score of 0. The controls had no staining. To increase the statistical power of the present study, the EMMPRIN expression staining variable was dichotomized, with the cut-off point set between the scores of 2 and 3. Thus patients with a score of 3 were defined as positive for EMMPRIN overexpression, whereas patients with scores of 2 were defined as negative for EMMPRIN overexpression. The frequency of EMMPRIN overexpression was significantly higher (P = 0.026) in TAAs with dissection (13 out of 19; 68.4 %) compared with TAAs without dissection (one out of seven; 14.3 %). Although the frequency of EMMPRIN overexpression was lower in AAAs (five out of 15; 33.3 %) than in TAAs with dissection, the difference did not achieve statistical significance (P = 0.082). There was also no significant difference in EMMPRIN expression between the groups of AAA and TAA without dissection (P = 0.616). No statistical difference was found between patients with Type A (nine out of 12; 75 %) and Type B (four out of seven; 57.1 %) (P = 0.617) aortic dissection. There was no correlation between the levels of EMMPRIN expression and sizes of aneurysms.
AngII stimulates EMMPRIN in human aortic SMCs
To investigate the potential role of EMMPRIN in AngIIinduced aneurysm formation, EMMPRIN protein levels in cultured human aortic SMCs following stimulation with AngII (10 −9 -10 −6 mol/l) for 24 h were analysed by Western blotting. The increase in EMMPRIN production occurred over an AngII concentration range of 10 −9 -10 −7 mol/l (P < 0.05 compared with unstimulated cells) with a maximum reached at 10 −6 mol/l (Figure 3) . To establish the cell-surface receptor mediating the response, SMCs were incubated with losartan, which acts as a competitive inhibitor of the AT 1 R, added 30 min before the addition of 10 −6 mol/l AngII. As shown in Figure 3 , AngII-stimulated EMMPRIN expression was inhibited by a 10-fold molar excess of losartan; a 100-fold excess of the inhibitor had similar results (results not shown). This finding suggests that AngII-induced EMMPRIN expression is specific and mediated by the AT 1 R.
DISCUSSION
In the present study, we have shown for the first time the presence and increased expression of EMMPRIN in human thoracic or abdominal aneurysmal aortas. The frequency of EMMPRIN overexpression was significantly higher in TAAs with dissection than in TAAs without dissection. In the aneurysmal wall, vascular SMCs are the main source of EMMPRIN. Furthermore, in vitro expression of EMMPRIN in human aortic SMCs was induced by AngII.
Aortic aneurysms are a common and lethal disease characterized by the degradation of important structural macromolecules, including fibrillar collagens and elastin. Most studies of MMPs have emphasized the key role of MMPs in the breakdown of ECM that ultimately leads to aortic aneurysm formation and development [1] [2] [3] [4] [5] [6] [7] 18] . Previous studies have shown that EMMPRIN
Figure 3 Western blot analysis of EMMPRIN expression upon AngII stimulation in human aortic SMCs
Representative immunoblots of three independent experiments are shown with antibodies that recognize EMMPRIN. Protein loading was normalized to the actin bands. EMMPRIN levels were significantly increased after stimulation with AngII (10 −9 -10 −6 mol/l) for 24 h. The AT 1 R antagonist losartan significantly inhibited these effects. * P < 0.01 compared with control, #P = 1.0 compared with control.
can alter the expression and activity of MMPs in various cell systems [8, 9, [15] [16] [17] . In our present study, expression of EMMPRIN was significantly increased in the aortic tissues from patients with TAAs and AAAs compared with control specimens. From the results of the present study and other reports [8, 9, [15] [16] [17] , it was expected that the up-regulation of EMMPRIN in aortic aneurysms may have multiple consequences because of its effects on MMP production. Whether these abnormalities are potential therapeutic targets deserves further investigation. Furthermore, we found a higher frequency of EMMPRIN overexpression in TAAs with dissection than in TAAs without dissection, which indicates that the specific role of EMMPRIN in different types of aortic aneurysm needs to be explored further. Our present results are consistent with previous studies indicating that MMPs are up-regulated in aortic dissection compared with aortic aneurysm without dissection [19] . In most cases the aetiology and histological features of thoracic and abdominal aneurysms are different, and it has been reported that the cellular expression of MMP-9 differs in the pathology of abdominal and thoracic aortas [20] . In the present study, no statistically significant difference in the frequency of EMMPRIN overexpression was found between AAAs and TAAs. Studies with larger samples are needed to confirm this result further.
It has been reported previously that EMMPRIN is essentially involved in MMP activation in monocytes and vascular SMCs in acute myocardial infarction [21] . During cellular interactions, EMMPRIN stimulates MMP-9 in monocytes and MMP-2 in SMCs, indicating that EMMPRIN may have a key regulatory role in MMP activity in cardiovascular pathologies [21] . However, in the present study, immunohistochemical evaluation showed increased levels of EMMPRIN in aortic aneurysmal lesions locally expressed mainly by SMCs, rather than monocytes/macrophages, although there was some inflammatory infiltrate present in the aneurysmal wall. Different forms of EMMPRIN can be produced by different modes of glycosylation and may be associated with different MMP expression patterns [22] . Therefore whether other forms of EMMPRIN are present in other cell types including macrophages in aortic aneurysms remains to be explored.
The role of the RAS (renin-angiotensin system) in the development of aortic aneurysms in animals and humans are being increasingly realized. The RAS has been suggested to be involved in the development of both AAAs and TAAs [14] . This has been demonstrated experimentally by the chronic subcutaneous infusion of AngII, which consistently leads to the development of AAAs in mice. AngII-induced AAAs have highly heterogenous cellular and ECM characteristics throughout the aorta that change markedly with the infusion duration [3, [10] [11] [12] [13] [14] . In our present study, human aortic SMCs which were stimulated with AngII had increased EMMPRIN expression. Thus the activity of EMMPRIN in vivo may represent a central mechanism for the effects of AngII on aortic aneurysm formation and development. However, the mechanism of how EMMPRIN may affect MMP activation in aortic aneurysms remains unclear. Experimental evidence has also demonstrated that antagonism of the AT 1 R prevents ascending aortic aneurysms in a murine model of Marfan's syndrome [12] . Our present study has shown that the AT 1 R antagonist losartan suppressed AngIIinduced EMMPRIN expression in human aortic SMCs, demonstrating an AT 1 R-mediated mechanism.
Our present study has several limitations that should be taken into account. First, a cause-and-effect relationship between EMMPRIN expression and aneurysm formation cannot be made because aneurysm specimens were limited to patients with advanced disease. Secondly, the sample size of our present study is relatively small. This is especially true for the subgroup analyses concerning EMMPRIN levels and aortic dissection. Thirdly, we speculate that the increased expression of EMMPIRN in the aneurysmal wall might affect the expression of MMPs and the organization of collagen fibrils and elastic fibres. However, because our study is a case-control study, no conclusions on causality can be drawn. Finally, reduced EMMPRIN levels in the control aorta could be due to EMMPRIN degradation during the process of autopsy. To test this possibility, we have obtained two aneurysmal samples from autopsy, performed immunohistochemical analysis and compared these with the data from surgical samples. Importantly, we did not find any noticeable differences between these two groups of samples (results not shown), so it is unlikely that EMMPRIN is unstable under autopsy conditions. Therefore reduced EMMPRIN levels in normal aorta obtained during autopsy were not due to its instability.
In conclusion, we have found that EMMPRIN expression is markedly increased in aortic aneurysm tissue. The results imply that EMMPRIN inhibition in vivo might reduce the propensity of the aorta to dilate and rupture, highlighting this protein as a potential new therapeutic target in patients with aortic aneurysmal diseases. Future studies should investigate whether EMMPRIN targets the prevention of unwanted MMP activity during aortic aneurysm processes. In addition, future studies involving the use of purified EMMPRIN and cultured SMCs are required to elucidate these steps fully in EMMPRIN-mediated MMP regulation.
